

Resource Summary Report

Generated by [RRID](#) on Aug 23, 2026

[pdCas9-NED](#)

RRID:Addgene_109358

Type: Plasmid

Proper Citation

RRID:Addgene_109358

Plasmid Information

URL: <http://www.addgene.org/109358>

Proper Citation: RRID:Addgene_109358

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:29524148](#)

Vector Backbone Description: Backbone Marker:Joung lab; Backbone Size:7636; Vector Backbone:pMLM3705 (Addgene plasmid #47754).; Vector Types:Mammalian Expression, CRISPR; Bacterial Resistance:Ampicillin

Comments: The DNA fragment encoding the effector domain is synthesized by PCR and cloned between the *Ascl* and *PacI* sites of pdCas9-NED to create in-frame fusion between dCas9 (D10A, H840A) and the effector domain. For experiments involving cell lines stably expressing the dCas9-effector domain fusion protein, the coding sequence of the effector domain can be excised from the pdCas9-NED-based recombinant plasmid and transferred into pHAGE EF1? dCas9-NED (Addgene plasmid #109369). Cloning the *Ascl*-*PacI* fragment between the *MluI* and *AsiSI* sites of pHAGE EF1? dCas9-NED preserves the reading frame of the fusion protein (Goubert et al., 2018).

Plasmid Name: pdCas9-NED

Record Creation Time: 20220422T221530+0000

Record Last Update: 20260815T080128+0000

Ratings and Alerts

No rating or validation information has been found for pdCas9-NED.

No alerts have been found for pdCas9-NED.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sarno F, et al. (2025) Epigenetic editing and epi-drugs: a combination strategy to simultaneously target KDM4 as a novel anticancer approach. *Clinical epigenetics*, 17(1), 105.

Wu DD, et al. (2023) Targeted epigenetic silencing of UCHL1 expression suppresses collagen-1 production in human lung epithelial cells. *Epigenetics*, 18(1), 2175522.

Sarno F, et al. (2022) Functional Validation of the Putative Oncogenic Activity of PLAU. *Biomedicines*, 11(1).

Gjaltema RAF, et al. (2020) KRAB-Induced Heterochromatin Effectively Silences PLOD2 Gene Expression in Somatic Cells and is Resilient to TGF β 1 Activation. *International journal of molecular sciences*, 21(10).